Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Real-world studies on the use of biologics in psoriasis (Pso) are increasing, but still scarce. Trough concentrations (C s) of interleukin-17 inhibitors (IL-17i) seem promising for clinical decision-making, but their value in daily practice has yet to be proven.
Objectives: To report on IL-17i effectiveness, treatment modifications and C use in our clinic.
Methods: Data were collected from IL-17i-treated Pso patients followed up in the PsoPlus clinic at the Dermatology department, Ghent University Hospital, Belgium. Descriptive statistics and Kaplan-Meier analysis were performed.
Results: A total of 111 patients were included, counting for 134 IL-17i courses (secukinumab, ixekizumab, and brodalumab). Fifty-five per cent of the patients were bio-naive prior to IL-17i initiation. During maintenance, merely 97.0% and 77% achieved near-complete and complete skin clearance, respectively. Major reasons for treatment modification were suboptimal response (63.0%) and safety issues (9.3%). Reported modifications were switch (25.4%), dose escalation (11.9%), dose de-escalation (6.7%), treatment association (6.0%) and IL-17i stop (3.0%). Overall drug survival was 69.0 months, without difference between the different IL-17i (p = 0.078). Ixekizumab tended to have the highest survival. Drug survival was higher in bio-naive subjects compared to bio-experienced subjects (p = 0.011). C was measured in 20 patients and interpreted post hoc. In 85%, the clinical decision was in accordance with the C (e.g. substantiated need for dose escalation). For the other cases, the C would have led to another clinical decision if known at that time.
Conclusions: This real-world study showed that IL-17i are very effective drugs for Pso, with ixekizumab as leading biologic. Prior bio-experience seemed to impact IL-17i drug survival. Treatment modifications were mainly performed in case of insufficient response, primarily via switch and dose escalation, and least frequently in ixekizumab patients. C might rationalize clinical decision-making; however, there is need for standardized algorithms to corroborate its use.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jdv.18827 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management of recurrent venous thromboembolism during anticoagulant treatment in patients with cancer: a prospective cohort study.
J Thromb Haemost
September 2025
Department of Medicine and Ageing Sciences, Gabriele D'Annunzio University, Chieti, Italy.
Background: Recurrent venous thromboembolism (VTE) is a common complication in patients with cancer-associated VTE. Limited data are available on treatment, particularly in patients receiving direct oral anticoagulants (DOACs). We aimed to evaluate current management strategies and outcomes in patients with cancer and recurrent VTE during treatment with low-molecular-weight heparin (LMWH) or DOACs.
View Article and Find Full Text PDFUrinary organs-at-risk for radiotherapy following radical prostatectomy: contouring guidelines on behalf of the Francophone Group of Urological Radiation Therapy (GFRU).
Pract Radiat Oncol
September 2025
Department of Radiation Oncology, Institut Bergonié, Bordeaux, France; Centre de Radiothérapie Charlebourg, La Défense, Groupe Amethyst, 65, avenue Foch, 92250 La Garenne-Colombes, France.
Purpose: Urinary toxicity following radical prostatectomy (RP) and postoperative radiotherapy (RT) includes urinary incontinence and vesicourethral anastomosis (VUA) strictures. With the increasing use of stereotactic body radiotherapy (SBRT), dose-escalation, and reirradiation within the prostate bed (PB), standardization of the definition of urinary organs at risk (OARs) in the post-RP setting is needed. This works aims to provide a comprehensive review of the anatomical and physiopathological changes occurring after RP, as well as to provide a consensus on urinary OARs delineation for prostate cancer (PCa) EBRT in the post-RP setting.
View Article and Find Full Text PDFPhase I dose-escalation trial of AMXT 1501 dicaprate plus difluoromethylornithine: a dual-agent approach targeting immunosuppressive polyamine metabolism.
ESMO Open
September 2025
Aminex Therapeutics, Inc., Kenmore, USA. Electronic address:
Background: Dysregulation of polyamine synthesis has been observed in various cancer cell types. A novel approach to depriving cancer cells of polyamines involves the use of difluoromethylornithine (DFMO) to block polyamine biosynthesis in combination with AMXT 1501, a potent inhibitor of polyamine transport. Preclinical mouse tumor models showed that the combination of AMXT 1501 plus DFMO had strong antitumor activity, together with evidence of a stimulated immune response against tumors.
View Article and Find Full Text PDFModel-Informed Precision Dosing of Vancomycin in Chinese Adult Patients Receiving Renal Replacement Therapy: Systematic Evaluation of Published Pharmacokinetic Models and Dosing Regimen Simulations.
Int J Antimicrob Agents
September 2025
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China; Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai 200040, China; National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan
Objectives: The pharmacokinetics of renally cleared vancomycin are significantly altered in critically ill patients undergoing renal replacement therapy (RRT), affecting the achievement of therapeutic targets. We evaluated the predictive performance of RRT patient-based PopPK models for model-informed precision dosing and subsequently simulated optimal dosing regimens for this population.
Methods: Six adult PopPK models were systematically identified and evaluated using a dataset of 226 concentrations from 23 adult patients on RRT from two study centers.
Utilization of intravenous posaconazole in pediatric patients undergoing hematopoietic stem cell transplant.
Transplant Cell Ther
September 2025
Division of Pharmacy, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Background: Pediatric patients undergoing hematopoietic stem cell transplant (HSCT) are at high risk for fungal infections including Candida, Aspergillus, and Mucorales necessitating the use of broad-spectrum antifungal agents such as posaconazole for prophylaxis and at times for treatment of invasive fungal infections. When first approved, posaconazole was limited to an immediate release oral suspension, which exhibited unreliable absorption dependent on co-administration with high fat meals. During HSCT, patients commonly have significant nausea, vomiting, and decreased enteral intake making this formulation particularly challenging.
View Article and Find Full Text PDF